Member Info for Laura2022

Trout

Point taken

But not why you choose to pick me up on my postings that are constructive and factual but NOT those (jaari etc) posting untruths

Point taken though

Bezt wishes

See my conversation with the company 2mths ago

PYC at £1.6mln market value is the next FAB/IMM

I've been buying sub 0 6p before Christmas

Yes bah

Some have been like this for 12-15mths and commented on no other shares

Looks like a busy weekend for the non- invested

Shows the value for the right drug pipeline

Yet another £1 Billion takeover announced today (13th January 2025) in our sector with GSK buying IDRx for 1 Billion upfront and 150 Million in extras. Come on Stephen Parker and John Reader get on with it please......

Details below:

· Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

· IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies

· Acquisition adds to GSK's growing portfolio in gastrointestinal (GI) cancers

· GSK to pay up to $1.15 billion

3

Nothing to concern

Miton have had redemptions across the board

And we don't just have the core business

We have newly emerged biostatistics

And also the potentially lucrative A.I dosing tools ( one with DosemeRx and the other NHS Trial one mentioned last week in the JV with NHS/beyond blood)

Plus our Virtual Tumour technology is fully fledged and now endorsed publicly

Porky

Why didn't you put this much effort into your DDDD due diligence or your cure3nt GDR holding which you said should be 50p+

Pmsl

Think I'll take the lead from the company rather than some sad keyboard warrior who clearly has no life on a Saturday night other than to plague a discussion group

You need help

This joint publication between Physiomics and Astellas demonstrates the impact of using modelling and simulation approaches to accelerate the development of innovative therapies across a range of therapeutic areas and throughout the entire drug development pathway, including early discovery and clinical development. The peer-reviewed article also demonstrates the power of Physiomics' Virtual Tumour platform in supporting world-leading pharmaceutical companies develop these important new therapies

Go and spend some time with your friend so or family

You're getting agitated

Imagine..!! 20+ posts on PYC...more than all your other shares combined

Strange how you ignored my challenge to you 24hrs ago..

You're mentally unwell and clearly a lonely lonely person

 this lifestyle business so they can cash out on any spike created:-

This sounds more like GDR where CEO earns £300k+ and has lost £4mln per year every year

Just 2 weeks ago you wished this for holders ?..maybe you just reverted to type once the alcohol wore off

Merry Christmas25 Dec 2024 06:32

Wishing Health, Wealth and Happiness to all and may 2025 be a better year.

Lets raise a glass today to loved ones, friends and absent friends forever in our hearts.

Merry Christmas

Pork’s X

Porky

I thought I was Seawolf and PM also ?

You're mentally unstable and need professional help

That trade is about 5% so should be a TR1

Population PK/PD modeling, the central methodology of pharmacometrics and the backbone of TDM-based precision dosing solutions, estimates drug exposure and efficacy over time in patients at the population level, or rather how the average patient responds to the drug. This approach allows for parameters associated with a drug to be quantified (e.g., clearance and volume of distribution), describes interindividual variability in drug PK/PD, and identifies predictive covariates. Another component of the pharmacometrics paradigm includes performing simulations to evaluate target attainment at given doses. Comparatively, ML focuses on making the most accurate predictions of outcomes. Although population PK/PD modeling can be considered a form of ML, a distinction between the 2 lies in the types of models used. The population PK/PD modeling approach commonly relies on developing structural models based on PK/PD concepts to provide pharmacologically and physiologically reasonable parameter estimations, whereas ML focuses on minimizing the prediction error using the most applicable model.

Particularly mentions areas PYC are involved in ( PK Modelling etc)

https://pmc.ncbi.nlm.nih.gov/articles/PMC11321806/

Looking ahead to 2025, Dr. Eccleston outlined plans to advance Cytolytix through preclinical pathways, evaluate three active programs, and expand the pipeline with new assets. In addition, legacy projects such as VAL201 and VAL401 continue to progress, with licensing deals and partnerships, including one with TheoremRx, further solidifying the company’s diverse pipeline. ValiRx remains steadfast in its mission to develop transformative therapies for unmet medical needs, with 2025 poised to be a critical year for clinical advancements and strategic growth. Stay tuned for updates as the company builds momentum in its pursuit of innovative cancer treatments.

Will take your own advice

worst

Posted in: GWMO

Posts: 538

Price: 0.0405

No Opinion

Filter is activated23 Aug 2024 12:42

I can only see reputable posts so whoever just posted is one who fell foul of the quality criteria so please leave the forum and seek interest elsewhere